KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables - Net (2020 - 2022)

Historic Receivables - Net for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Q2 2022 value amounting to $21000.0.

  • Recursion Pharmaceuticals' Receivables - Net fell 5714.29% to $21000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $21000.0, marking a year-over-year decrease of 5714.29%. This contributed to the annual value of $34000.0 for FY2021, which is 7820.51% down from last year.
  • As of Q2 2022, Recursion Pharmaceuticals' Receivables - Net stood at $21000.0, which was down 5714.29% from $34000.0 recorded in Q1 2022.
  • Recursion Pharmaceuticals' 5-year Receivables - Net high stood at $156000.0 for Q4 2020, and its period low was $21000.0 during Q2 2022.
  • Its 3-year average for Receivables - Net is $57000.0, with a median of $34000.0 in 2021.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Receivables - Net tumbled by 7820.51% in 2021, and later crashed by 5211.27% in 2022.
  • Quarter analysis of 3 years shows Recursion Pharmaceuticals' Receivables - Net stood at $156000.0 in 2020, then crashed by 78.21% to $34000.0 in 2021, then plummeted by 38.24% to $21000.0 in 2022.
  • Its Receivables - Net stands at $21000.0 for Q2 2022, versus $34000.0 for Q1 2022 and $34000.0 for Q4 2021.